Detalhe da pesquisa
1.
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-d]pyrimidine RET Inhibitors.
ACS Med Chem Lett
; 12(12): 1912-1919, 2021 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34917254
2.
Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.
ACS Med Chem Lett
; 11(4): 558-565, 2020 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292564
3.
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
J Med Chem
; 63(8): 3868-3880, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31940200
4.
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.
J Med Chem
; 63(19): 10773-10781, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32667203
5.
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents.
Hepatol Commun
; 3(8): 1085-1097, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31388629
6.
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
J Med Chem
; 60(24): 9960-9973, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29148806